News

Thumbs-up for IMI2
Enlarge image

FundingEU

Thumbs-up for IMI2

17.04.2014 - The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

The public-private research programme Innovative Medicines Initiative (IMI2) is jointly run by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA)  and aims to improve the process of developing new drugs and treatments by supporting cooeration in reaserch and development. The European Parliament’s Industry, Research and Energy (ITRE) committee voted in favour of the second initiative which will run from 2014 for ten years and will have a budget of approximately €3bn.

The Parliament was consulted for advice only: It does not have co-decision rights on this subject, which is left to the European Commission and the Council, who represent the 28 EU member states. However, the Green group voted against the initiative, citing the overwhelming influence of large companies, who are gaining an advantage by setting their own research objectives, leaving SMEs behind. EFPIA, on the other hand, welcomed the decision and commented: “IMI2 will take the collaborative vision of IMI even further in its service to patients and the public health agenda. The first five big questions to be addressed by IMI2 include neuro-degeneration, metabolic disorders, immune-mediated diseases, infections and translational safety.” The launch of IMI2 and first calls for proposals are planned for July.

The first initiative ran out in 2013 after running for six years. The partnership had access to a budget of €2bn, with half of the funding coming from the Commission through the Horizon 2020 programme, and the other half from EFPIA. It funded projects in areas such as antibiotics, data integration and drug screening.

© eurobiotechnews.eu/um

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/4.html?cHash=107d830ec6da8858ab08a5c8e9dd914b&sort=desc

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • CO.DON (D)3.30 EUR88.6%
  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR50.8%

FLOP

  • CYTOS (CH)0.17 CHF-94.1%
  • BIONOR PHARMA (N)2.11 NOK-49.0%
  • GW PHARMACEUTICALS (UK)219.25 GBP-39.6%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6143.9%
  • IXICO (UK)71.50 GBP807.4%
  • PLETHORA (UK)10.62 GBP585.2%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.7%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 16.04.2014